SEROMAX

Blood Collection Kit

CodeProduct Name
30055

Sengenics SEROMAX blood collection kit

Order on Science Exchange

Product Highlights

Product Description

SEROMAX is a sample collection kit which only requires a pin-prick amount of blood for quantifying antibodies or autoantibodies. Conventional antibody sample collection methods require patients to visit a clinical site where a physician would commonly need to draw a minimum of 0.5 ml of blood. This is followed by costly cold chain processes before the sample reaches a test laboratory for assay and analysis. By using a proprietary matrix to stabilise antibodies, the SEROMAX kit simplifies this process, enabling shipping at room temperature. This is then combined with the ultra-high sensitivity of KREX protein arrays to produce results that are identical to conventionally collected samples.

Key Applications

  • Safe and practical collection of samples for clinical trials, without requiring a cold chain, hence improving patient recruitment
  • Enable patients to self-collect blood samples following a flare-up event during a drug clinical trial
  • Benefit researchers working in the COVID-19 R&D space with sample collection for seroprevalence studies and for monitoring of vaccine trials

Specifications

Product Namexx
Product Name

Sengenics SEROMAX blood collection kit

Platform

Complementary to the Sengenics range of protein array which includes Immunome, ImmuSAFE, OncoREX p53, CTA and KREX-based custom array

Content

SEROMAX Blood Card x 1
SEROMAX sleeve x 1
Biohazard bag x 1
Lancet x 3
Alcohol Swab x 3
Dessicant x 1

Sample type

Whole blood
*please contact us for requirements of other types of samples

Sengenics - Functional Proteomics | Krex Technology | Protein Microarray Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics UK Registered in England and Wales no. 12889389